• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


             

INTERRUPT AF PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Progress Adequate
Application Number P150005 S035/ PAS001
Date Current Protocol Accepted  
Study Name INTERRUPT AF PAS
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Objective Performance Criterion
Analysis Type Analytical
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The INTERRUPT AF study is a global, prospective, non-randomized, multicenter study, to assess acute and long-term outcomes for the Rhythmia Mapping System in conjunction with the Blazer and IntellaNav Open-Irrigated Ablation Catheters to treat Paroxysmal Atrial Fibrillation for de novo cases.
Study Population Description The study will enroll patients with symptomatic drug-refractory paroxysmal atrial fibrillation undergoing AF ablation.
Sample Size The sample size of 415 subjects’ enrollment at 25-50 centers worldwide will ensure the minimum of 329 treatment subjects in the study. The calculation of sample size is driven by hypothesis. The sample size required to assess the Primary Safety Endpoint hypothesis was 329.

The assumptions for the sample size calculation were an expected primary safety endpoint event-free rate at one year of 90%, a performance goal of 85%, an alpha of 0.05, 80% power, and an expected attrition (per year) of 7.5%. The performance goal of 85% is based on the Primary Safety Endpoint results from the ZERO-AF clinical study data (G120082).

Data Collection The primary safety endpoint will be evaluated by the primary safety event-free rate at 12 months post-procedure. Primary safety events will consist of a composite of acute primary safety events (events occurring within seven days post-procedure or hospital discharge, whichever is later), and chronic primary safety events (events occurring through 3 months or 12 months post-procedure).

Acute primary safety events will be defined as the following:

• Death • Myocardial infarction (MI) Vagal Nerve Injury/Gastroparesis • Transient ischemic attack (TIA) • Stroke/Cerebrovascular accident (CVA) • Thromboembolism • Pericarditis • Cardiac tamponade/perforation • Pneumothorax • Vascular access complications • Pulmonary edema/heart failure • AV block

Chronic primary safety events will be defined as the following:

• Atrial esophageal fistula (occurring through 3 months) • Pericardial effusion (ocurring through 3 months) • Pulmonary vein stenosis (symptomatic and requiring intervention) (occurring through 12 months)

Primary effectiveness events will be defined as the following:

• Acute procedural failure • More than one repeat procedure during the blanking period (90 days post index procedure) • Documented atrial fibrillation, or new onset of atrial flutter or atrial tachycardia event (= 30 seconds in duration from an event monitor or Holter Monitor, or from a 10 second 12-lead EKG) between 91 days and 365 days post index procedure • Any of the following interventions for atrial fibrillation, or new onset of atrial flutter or atrial tachycardia between 91 days and 365 days post index procedure:

• Repeat procedure • Cardioversion • Prescribed any anti-arrhythmic drugs* (AAD*)

*AADs for endpoint will consist of all Class I/III and any Class II/IV medications taken for control of AF/AT/AFL recurrence

The objective of the secondary effectiveness endpoint is that the secondary effectiveness event-free rate at 12 months post-procedure in each cohort is greater than the specified performance goal 50% for De Novo Cohort.

Secondary effectiveness events will be defined as the following:

Acute procedural failure • More than one repeat procedure during the blanking period (90 days post index procedure) • Documented symptomatic atrial fibrillation, or new onset of atrial flutter or atrial tachycardia event (= 30 seconds in duration from an event monitor or Holter, or from a 10 second 12-lead EKG) between 91 days and 365 days post index procedure • Any of the following interventions for atrial fibrillation, or new onset of atrial flutter or atrial tachycardia between 91 days and 365 days post index procedure:

• Repeat procedure • Cardioversion • Prescribed a higher dose of any AAD* documented at baseline • Prescribed a new AAD* not documented at baseline

*AADs for endpoint will consist of all Class I/III and Class II/IV medications taken for control of AF/AT/AFL recurrence

Tertiary Endpoint:

• • Chronic Effectiveness: Evaluation of chronic recurrence at 24 months and 36 months.

• • Center Experience: Outcomes in centers performing five or more procedures using the Blazer OI catheter during the ZERO AF IDE study will be compared to all other centers in the study using descriptive statistics.

• Safety: Reportable Adverse Events rates at 12, 24 and 36 months. o All Serious Adverse Events

o All Study Procedure-Related Adverse Events

o All Study Device-Related Adverse Events

o All Study Device Deficiencies

o Unanticipated Adverse Device Effects/Unanticipated Serious Adverse Device Effects

o previously not defined in the Directions For Use.

Reportable events include:

• Effectiveness: Acute Procedural Success Rate

Follow-up Visits and Length of Follow-up The patients in De Novo cohort will be followed for 3 years.


INTERRUPT AF PAS Schedule

Report Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
six month report 01/30/2019 01/31/2019 Overdue/Received
interim report 04/26/2019 04/26/2019 On Time
one year report 11/01/2019 10/31/2019 On Time
18 month report 05/01/2020    
two year report 11/01/2020    
three year report 11/01/2021    
four year report 11/01/2022    


Contact Us

Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Related Links

-
-